Pfizer Current Ratio 2010-2022 | PFE

Current and historical current ratio for Pfizer (PFE) from 2010 to 2022. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations. Pfizer current ratio for the three months ending June 30, 2022 was 1.42.
Pfizer Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2022-06-30 $67.47B $47.41B 1.42
2022-03-31 $54.42B $39.27B 1.39
2021-12-31 $59.69B $42.67B 1.40
2021-09-30 $57.90B $41.80B 1.39
2021-06-30 $48.81B $35.66B 1.37
2021-03-31 $39.53B $26.65B 1.48
2020-12-31 $35.07B $25.92B 1.35
2020-09-30 $47.74B $34.15B 1.40
2020-06-30 $46.42B $32.72B 1.42
2020-03-31 $34.74B $33.89B 1.03
2019-12-31 $32.80B $37.30B 0.88
2019-09-30 $33.46B $36.97B 0.91
2019-06-30 $47.07B $32.03B 1.47
2019-03-31 $45.29B $29.42B 1.54
2018-12-31 $49.93B $31.86B 1.57
2018-09-30 $41.58B $29.01B 1.43
2018-06-30 $37.30B $32.16B 1.16
2018-03-31 $34.84B $27.37B 1.27
2017-12-31 $41.14B $30.43B 1.35
2017-09-30 $40.29B $28.22B 1.43
2017-06-30 $36.39B $27.18B 1.34
2017-03-31 $35.88B $24.86B 1.44
2016-12-31 $38.95B $31.12B 1.25
2016-09-30 $38.50B $34.76B 1.11
2016-06-30 $43.85B $32.10B 1.37
2016-03-31 $41.30B $28.74B 1.44
2015-12-31 $43.80B $29.40B 1.49
2015-09-30 $45.00B $27.85B 1.62
2015-06-30 $51.72B $24.14B 2.14
2015-03-31 $49.44B $20.22B 2.45
2014-12-31 $55.60B $21.59B 2.58
2014-09-30 $56.99B $19.92B 2.86
2014-06-30 $58.29B $21.94B 2.66
2014-03-31 $57.79B $24.79B 2.33
2013-12-31 $56.24B $23.37B 2.41
2013-09-30 $59.50B $20.37B 2.92
2013-06-30 $61.44B $23.45B 2.62
2013-03-31 $64.76B $27.54B 2.35
2012-12-31 $64.83B $29.19B 2.22
2012-09-30 $57.13B $29.13B 1.96
2012-06-30 $58.77B $30.80B 1.91
2012-03-31 $54.86B $27.09B 2.03
2011-12-31 $60.82B $28.91B 2.10
2011-09-30 $62.73B $27.86B 2.25
2011-06-30 $60.48B $30.47B 1.99
2011-03-31 $58.24B $29.17B 2.00
2010-12-31 $61.01B $28.64B 2.13
2010-09-30 $54.09B $24.17B 2.24
2010-06-30 $51.10B $24.68B 2.07
2010-03-31 $49.92B $25.92B 1.93
2009-12-31 $61.67B $37.23B 1.66
2009-09-30 $73.78B $23.99B 3.08
2009-06-30 $71.55B $26.11B 2.74
2009-03-31 $54.25B $23.34B 2.32
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $281.235B $81.288B
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $434.603B 16.55
Eli Lilly (LLY) United States $292.730B 37.12
AbbVie (ABBV) United States $252.131B 10.71
Novo Nordisk (NVO) Denmark $243.269B 32.09
Merck (MRK) United States $230.579B 12.04
Novartis AG (NVS) Switzerland $189.576B 13.98